Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price ...
Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...
HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS – Free Report) in a report published on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. A ...
Alumis announced positive Phase 2 OLE results for ESK-001, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing sustained clinical improvements. Alumis Inc. has announced positive 52 ...
Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback